- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04289649
K-924 Phase III Confirmatory Study
November 26, 2023 updated by: Kowa Company, Ltd.
A Phase III, Multicenter, Randomized, Clinial Trial to Evaluate the Efficacy and Safety of K-924 in Patienta With Hypercholesterolemia.
A multicenter, active-controlled, randomized, double-blind comparative study to compare the efficacy and safety of K-924 LD tablet or K-924 HD tablet to pitavastatin 2 mg or 4 mg in patienta with hypercholesterolemia.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
293
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Osaka, Japan
- Medical Corporation Heishinkai OCROM Clinic
-
Osaka, Japan
- Medical Corporation Heishinkai OPHAC Hospital
-
Tokyo, Japan
- Medical Corporation Heishinkai ToCROM Clinic
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Patients with hypercholesterolemia had to be age 20 years or older at written informed consent (ICF)
- Patients who have been on a diet and / or exercise regimen more than 12 weeks before the screening
Those whose LDL-C (Friedewald formula) at the screening any of the following in the category classification based on Japan Atherosclerosis Society guidelines for prevention Atherosclerotic Cardiovascular Disease 2017
- Low risk of primary prevention : LDL-C => 160 mg/dL
- Medium risk of primary prevention : LDL-C => 140 mg/dL
- High risk of primary prevention : LDL-C => 120 mg/dL
Exclusion Criteria:
- Patients with a history of myopathy or rhabdomyolysis due to pitavastatin or ezetimibe
- Patients with a history of hypersensitivity due to pitavastatin or ezetimibe
- Patients with severe liver damage (Child Pugh Class B or higher) or biliary obstruction
- Pregnant women, lactating women, women planning to become pregnant or lactating during the study period, or pregnant women who do not use specific contraceptive methods
- Patients whose CK is 3 times or more of the upper limit of the reference value at screening
- Patients whose AST and ALT is 2 times or more of the upper limit of the reference value at screening
- Patients wiht type 1 diabetes or uncontrolled type 2 diabetes as defined HbA1c 8% or more at screening
- Patients with uncontrolled hypertension as defined systolic blood pressure of 160 mmHg or more or diastolic blood pressure of 100 mmHg or more at screening
- Patients with eGFR of less than 30 mL / min / 1.73 m² at screening or dialysis
- Patients with heart failure class III or higher according to NYHA cardiac function classification
- Patients with uncontrolled arrhythmia
- Patients with uncontrolled metabolic endocrine disease
- Patients with a history of coronary artery disease or patient with familial hypercholesterolemia
- Patients with malignant tumors or who are judged to have a high possibility of relapse
- Patients who have collected 200 mL or more within 4 weeks before screening, 400 mL or more of blood within 12 weeks for males or 16 weeks for females, or within 2 weeks for (Plasma component / platelet component)
- Persons with a history of severe drug allergy (anaphylactic shock, etc.)
- Patients who need contraindicated drugs during the study period after obtaining consent
- Patients with TG of 400 mg / dL or more at screening
- Patients who have LDL apheresis
- Patients with malabsorption or history, or who have undergone gastrointestinal surgery (excluding appendectomy, hernia treatment, etc.) that may affect absorption.
- Patients with Alcohol or drug addiction
- Patients who participate in other clinical trials within 16 weeks prior to study drug administration and who are administered non-placebo investigational drugs, or who participate in other clinical trials concurrently with this study
- Patients who have received K-924
- Patients who judged to be inappropriate by the Investigator or Investigator
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: K-924 LD
K-924 LD tablet once daily
|
Pitavastatin 2 mg / Ezetimibe 10 mg tables
|
Experimental: K-924 HD
K-924 HD tablet once daily
|
Pitavastatin 4 mg / Ezetimibe 10 mg tables
|
Active Comparator: Pitavastatin 2 mg
K-924 LD Placebo tablet once daily
|
Pitavastain 2 mg
|
Active Comparator: Pitavastatin 4 mg
K-924 HD Placebo tablet once daily
|
Pitavastain 4 mg
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Efficacy : % change from baseline in LDL-C (Friedewald formula) (mg / dL)
Time Frame: Week 12
|
Week 12
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Efficacy : % change or change from baseline in LDL-C (mg / dL)
Time Frame: From baseline upto week 12
|
From baseline upto week 12
|
Efficacy : % change or change from baseline in non-HDL-C (mg / dL)
Time Frame: From baseline upto week 12
|
From baseline upto week 12
|
Efficacy : % change or change from baseline in HDL-C (mg / dL)
Time Frame: From baseline upto week 12
|
From baseline upto week 12
|
Efficacy : % change or change from baseline in Total Cholesterol (mg / dL)
Time Frame: From baseline upto week 12
|
From baseline upto week 12
|
Efficacy : % change or change from baseline in TG (mg / dL)
Time Frame: From baseline upto week 12
|
From baseline upto week 12
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 2, 2020
Primary Completion (Actual)
November 21, 2020
Study Completion (Actual)
November 21, 2020
Study Registration Dates
First Submitted
February 27, 2020
First Submitted That Met QC Criteria
February 27, 2020
First Posted (Actual)
February 28, 2020
Study Record Updates
Last Update Posted (Actual)
November 29, 2023
Last Update Submitted That Met QC Criteria
November 26, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- K-924-02
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypercholesterolemia
-
National Medical Research Center for Therapy and...Moscow State University of Medicine and DentistryRecruitingMedication Adherence | Adherence, Medication | Treatment Adherence | Familial Hypercholesterolemia | Motivational Interviewing | Adherence, Patient | Treatment Adherence and Compliance | Patient Compliance | Adherence | Hypercholesterolemia, Familial | Patient Adherence | Hypercholesterolemia, Autosomal Dominant and other conditionsRussian Federation
-
Direct PlantesUnknownHYPERCHOLESTEROLEMIAFrance
-
Chong Kun Dang PharmaceuticalRecruitingPrimary HypercholesterolemiaKorea, Republic of
-
Addpharma Inc.CompletedPrimary HypercholesterolemiaKorea, Republic of
-
JW PharmaceuticalCompletedPrimary HypercholesterolemiaKorea, Republic of
-
Hanmi Pharmaceutical Company LimitedCompletedPrimary HypercholesterolemiaKorea, Republic of
-
Provident Clinical ResearchGlaxoSmithKlineUnknownPrimary HypercholesterolemiaUnited States
-
Organon and CoCompletedPrimary Hypercholesterolemia | Homozygous Familial Hypercholesterolemia
-
Boryung Pharmaceutical Co., LtdRecruitingPrimary HypercholesterolemiaKorea, Republic of
-
Ahn-Gook Pharmaceuticals Co.,LtdRecruitingPrimary HypercholesterolemiaKorea, Republic of
Clinical Trials on K-924 LD
-
Impax Laboratories, LLCCompletedParkinson's DiseaseUnited States
-
Emergex Vaccines Holding Ltd.University of Lausanne Hospitals; Center for Primary Care and Public Health...Completed
-
Assistance Publique - Hôpitaux de ParisIltoo PharmaCompletedAllergic Rhinoconjunctivitis to Birch Pollen | With a Positive Skin Prick Test to Birch PollenFrance
-
Abiomed Inc.CompletedCardiac SurgeryUnited States
-
Impax Laboratories, LLCCompletedA Study To Evaluate The Safety And Efficacy Of IPX066 In Subjects With Parkinson's Disease (APEX-PD)Parkinson's DiseaseUnited States, Canada, Estonia, Latvia, Lithuania, Romania, Ukraine
-
Impax Laboratories, LLCCompletedIdiopathic Parkinson's DiseaseUnited States
-
Emergex Vaccines Holding Ltd.University of Lausanne Hospitals; Center for Primary Care and Public Health...CompletedCOVID-19 | Coronavirus | SARS-CoV-2 InfectionSwitzerland
-
Kallyope Inc.RecruitingObesity | Type 2 Diabetes Mellitus (T2DM)United States
-
Tabba Heart InstituteInnoTherapy IncRecruiting